KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial.

Daniel E Spratt, Vinnie Y T Liu, Jeff Michalski, Elai Davicioni, Alejandro Berlin, Jeffry P Simko, Jason A Efstathiou, Phuoc T Tran, Howard M Sandler, William A Hall, Darby J S Thompson, Matthew B Parliament, Ian S Dayes, Rohann Jonathan Mark Correa, John M Robertson, Elizabeth M Gore, Desiree E Doncals, Eric Vigneault, Luis Souhami, Theodore G Karrison, Felix Y Feng

Int J Radiat Oncol Biol Phys 117(2) 370-377

PMID37137444
PMCIDPMC10949135
DOI10.1016/j.ijrobp.2023.04.010
发表日期2023-05-03
入排依据:The report is a secondary analysis of a genomic classifier in a Phase III randomized trial of radiation therapy doses. While it meets oncology, human, randomized, phase, and time-to-event criteria, it lacks a drug-containing intervention. The intervention is non-drug (radiation therapy), and the analysis is focused on a biomarker (genomic classifier) rather than being the original report of a drug trial.
摘要

摘要

PURPOSE: Intermediate-risk prostate cancer is a heterogeneous disease state with diverse treatment options. The 22-gene Decipher genomic classifier (GC) retrospectively has shown to improve risk stratification in these patients. We assessed the performance of the GC in men with intermediate-risk disease enrolled in NRG Oncology/RTOG 01-26 with updated follow-up. METHODS AND MATERIALS: After National Cancer Institute approval, biopsy slides were collected from NRG Oncology/RTOG 01-26, a randomized phase 3 trial of men with intermediate-risk prostate cancer randomized to 70.2 Gy versus 79.2 Gy of radiation therapy without androgen deprivation therapy. RNA was extracted from the highest-grade tumor foci to generate the locked 22-gene GC model. The primary endpoint for this ancillary project was disease progression (composite of biochemical failure, local failure, distant metastasis, prostate cancer-specific mortality, and use of salvage therapy). Individual endpoints were also assessed. Fine-Gray or cause-specific Cox multivariable models were constructed adjusting for randomization arm and trial stratification factors. RESULTS: Two-hundred fifteen patient samples passed quality control for analysis. The median follow-up was 12.8 years (range, 2.4-17.7). On multivariable analysis, the 22-gene GC (per 0.1 unit) was independently prognostic for disease progression (subdistribution hazard ratio [sHR], 1.12; 95% confidence interval [CI], 1.00-1.26; P = .04), biochemical failure (sHR, 1.22; 95% CI, 1.10-1.37; P < .001), distant metastasis (sHR, 1.28; 95% CI, 1.06-1.55; P = .01), and prostate cancer-specific mortality (sHR, 1.45; 95% CI, 1.20-1.76; P < .001). Ten-year distant metastasis in GC low-risk patients was 4% compared with 16% for GC high-risk patients. In patients with lower GC scores, the 10-year difference in metastasis-free survival rate between arms was -7%, compared with 21% for higher GC patients (P-interaction = .04). CONCLUSIONS: This study represents the first validation of a biopsy-based gene expression classifier, assessing both its prognostic and predictive value, using data from a randomized phase 3 trial of intermediate-risk prostate cancer. Decipher improves risk stratification and can aid in treatment decision-making in men with intermediate-risk disease.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。